Dengue Vaccine Initiative welcomes latest progress in vaccine development

Clinical trial results indicate advance in Dengue vaccine research

2012-09-11

(Press-News.org) WASHINGTON, D.C.—September 11, 2012—Today, The Dengue Vaccine Initiative (DVI) welcomed new clinical trial results that reveal progress in developing the first-ever dengue vaccine. In a publication in The Lancet, pharmaceutical company Sanofi Pasteur reported results from the first study conducted to evaluate the efficacy of any dengue vaccine candidate against clinical dengue disease in a population naturally exposed to dengue.

Dengue vaccine development efforts have been difficult because dengue is caused by four different related viruses, known as DENV 1, 2, 3 and 4. The results published in today's study found that Sanofi's vaccine candidate was effective against DENV 1, 3 and 4, but DENV 2 appeared to be resistant to vaccine in this trial. The vaccine candidate, called CYD-TDV, was tested on a group of 4,002 schoolchildren in Thailand, where dengue is known to be endemic.

"While there is still much work to be done, these clinical trials mark a decisive step forward in the development of a safe and effective vaccine," said Dr. Luiz da Silva, Director of the Dengue Vaccine Initiative. "We support the progress made by Sanofi Pasteur as well as efforts by other organizations to deliver a vaccine to populations in endemic countries."

There is no vaccine available to treat or prevent dengue fever. While vaccines have been under development since the 1940s, little progress had been made until recently. Reported dengue cases have increased from an annual average of fewer than 300,000 cases during the 1980s to nearly 1 million per annum from 2000 to 2005.The WHO estimates that there are 50 to 100 million dengue infections a year.

"This is a dramatic increase in dengue incidence rates, and yet it's very likely that the numbers still do not reflect the full scope of the problem," said Dr. Ciro de Quadros, Executive Vice President of the Sabin Vaccine Institute. "An exact number is difficult to determine due to a lack of accurate diagnostic testing and common misdiagnosis."

Dengue is the most common mosquito-borne viral disease, with more than 2.5 billion people at risk for the disease globally, resulting in an estimated 21,000 deaths per year. Dengue symptoms can range from mild, flu-like symptoms to severe circulatory failure, coma and death. Most outbreaks occur during the rainy season in endemic countries like Thailand and Brazil, when mosquito populations are high.

Currently, there are several dengue vaccines in various stages of development, with four candidates, including Sanofi Pasteur's, in clinical trial stages. The results of this first study, a phase IIb clinical trial, are not yet sufficient to prove or disprove efficacy of CYD-TDV. However, Sanofi has already begun phase III studies among 31,000 children in Asia and Latin America. These studies will provide further information, including pivotal efficacy results and additional safety data.

"In addition to saving lives and reducing illness, a dengue fever vaccine, once introduced, will have significant positive impacts on the global economy," added Dr. Orin Levine, Executive Director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health. "The cost of dengue fever in the Americas alone is estimated to be $2.1 billion annually, and the burden of lost wages and productivity, along with the cost of healthcare, takes a great toll in endemic countries across the globe."

###DVI is working to lay the groundwork for dengue vaccine introduction in endemic areas so that, once licensed, vaccines to prevent dengue will be swiftly adopted by countries most in need. The DVI consortium, which includes the Sabin Vaccine Institute, the International Vaccine Institute (IVI), the World Health Organization (WHO) and the International Vaccine Access Center (IVAC), builds on the momentum and capabilities of the Pediatric Dengue Vaccine Initiative (PDVI) and focuses on creating an enabling environment for vaccine introduction and on maintaining a pipeline of vaccine candidates.

DVI's advocacy and communications activities are managed by the Sabin Vaccine Institute, a non-profit global health advocacy and resource mobilization organization based in Washington, D.C.

About the Dengue Vaccine Initiative The Dengue Vaccine Initiative (DVI) was established in 2010 to build on the work of the Pediatric Dengue Vaccine Initiative and to further awareness of the need to support the development and use of dengue vaccines. The goal of the DVI is to accelerate the introduction of safe and broadly protective vaccines into the national immunization programs of endemic and developing countries. DVI works with scientists, vaccine experts and policymakers from concept to implementation, promoting the development of dengue vaccines while also advocating with governments worldwide to ensure the swift adoption and distribution of a vaccine to those most in need. To learn more visit www.denguevaccines.org.

About Sabin Vaccine Institute Sabin Vaccine Institute is a non-profit, 501(c)(3) organization of scientists, researchers and advocates dedicated to reducing needless human suffering from infectious and neglected tropical diseases through prevention and treatment. Sabin works with governments, academic institutions, scientists, medical professionals and other non-profit organizations to provide short and long-term solutions for some of the globe's toughest health care challenges. Since its founding in 1993 in honor of the oral polio vaccine developer, Dr. Albert B. Sabin, the Institute has been at the forefront of global efforts to eliminate, prevent and cure infectious and neglected tropical diseases by developing new vaccines, establishing international networks, and advocating for effective and efficient delivery of preventions and treatments to the world's poor. www.sabin.org

ELSE PRESS RELEASES FROM THIS DATE:

LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS

2012-09-11

New Orleans, LA – A research study conducted by Dr. Jesus Lovera, Assistant Professor of Neurology at LSU Health Sciences Center New Orleans, and colleagues has found that the herbal supplement Ginkgo biloba does not improve cognitive function in patients with Multiple Sclerosis (MS.) Cognitive impairment affects 40-60% of people with MS, most commonly affecting their processing speed, memory, and executive skills. The research findings were published online ahead of print in Neurology on September 5, 2012. This study followed up on a promising earlier small study by ...

Who (and what) can you trust?

2012-09-11

People face this predicament all the time—can you determine a person's character in a single interaction? Can you judge whether someone you just met can be trusted when you have only a few minutes together? And if you can, how do you do it? Using a robot named Nexi, Northeastern University psychology professor David DeSteno and collaborators Cynthia Breazeal from MIT's Media Lab and Robert Frank and David Pizarro from Cornell University have figured out the answer. The findings were recently pub¬lished in the journal Psychological Science, a journal of the Association for ...

Analyzing the 'Facebook Effect' on organ and tissue donation

2012-09-11

(Garrison, NY) When Facebook introduced a feature that enables people to register to become organ and tissue donors, thousands did so, dwarfing any previous donation initiative, write Blair L. Sadler and Alfred M. Sadler, Jr., in a commentary in Bioethics Forum, the blog of the Hastings Center Report, which analyzes the "Facebook effect" on donation. The Sadlers, Founding Fellows of The Hastings Center, helped draft the Uniform Anatomical Gift Act, established in 1968 to standardize state laws on the donation of organs and tissue after death. Blair Sadler, a lawyer, is ...

Reconstructed 1918 influenza virus has yielded key insights, scientists say

2012-09-11

WHAT: The genetic sequencing and reconstruction of the 1918 influenza virus that killed 50 million people worldwide have advanced scientists' understanding of influenza biology and yielded important information on how to prevent and control future pandemics, according to a new commentary by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and several other institutions. By sequencing the 1918 virus, researchers were able to confirm that the viruses that caused influenza pandemics in 1957, 1968, ...

Researchers improve gene therapy technique for children with immune disorder

2012-09-11

By including chemotherapy as a conditioning regimen prior to treatment, researchers have developed a refined gene therapy approach that safely and effectively restores the immune system of children with a form of severe combined immunodeficiency (SCID), according to a study published online today in Blood, the Journal of the American Society of Hematology (ASH). SCID is a group of rare and debilitating genetic disorders that affect the normal development of the immune system in newborns. Infants with SCID are prone to serious, life-threatening infections within the first ...

What do saving money and losing weight have in common?

2012-09-11

Consumers will pay more when they are given different options to pursue short-term goals, but will pay more for similar options when pursuing long-term goals, according to a new study in the Journal of Consumer Research. "Many of the benefits of pursuing self-control goals such as being healthy are experienced in the future. Thus, a key component of our success in meeting our goals is the ability to remain motivated. One way for consumers to manage motivation is to strategically choose the options available to them in pursuing their goals," write authors Jordan Etkin ...

Parents of babies with sickle cell trait are less likely to receive genetic counseling, study says

2012-09-11

Ann Arbor, Mich. — Parents of newborns with the sickle cell anemia trait were less likely to receive genetic counseling than parents whose babies are cystic fibrosis carriers, a new study from the University of Michigan shows. University of Michigan researchers found that 20 percent of physicians reported their patients with newborns carrying the sickle cell trait did not get any genetic counseling. In contrast, parents of babies who were cystic fibrosis carriers received more counseling overall (92 percent vs. 80 percent). The research was published online in the ...

Report recommends cost-effective plan to strengthen US defense against ballistic missile attacks

2012-09-11

WASHINGTON ― To more effectively defend against ballistic missile attacks, the U.S. should concentrate on defense systems that intercept enemy missiles in midcourse and stop spending money on boost-phase defense systems of any kind, concludes a new, congressionally mandated report from a committee of the National Research Council. The committee was asked to assess the feasibility, practicality, and affordability of U.S. boost-phase missile defenses and compare them with other alternatives for countering limited nuclear or conventional ballistic missile attacks ...

At least 200,000 tons of oil and gas from Deepwater Horizon spill consumed by gulf bacteria

2012-09-11

Researchers from the University of Rochester and Texas A&M University have found that, over a period of five months following the disastrous 2010 Deepwater Horizon explosion and oil spill, naturally-occurring bacteria that exist in the Gulf of Mexico consumed and removed at least 200,000 tons of oil and natural gas that spewed into the deep Gulf from the ruptured well head. The researchers analyzed an extensive data set to determine not only how much oil and gas was eaten by bacteria, but also how the characteristics of this feast changed with time. "A significant amount ...

Trouble in paradise: Does nature worship harm the environment?

2012-09-11

Consumers nurture romantic ideas of nature by engaging in practices that are often harmful to the environment, according to a new study in the Journal of Consumer Research. Could eco-friendly products provide a solution? "Nature is often considered the ideal place to escape from everyday life. Consumers enjoy romantic escapes from culture in contexts as diverse as surfing, tropical island holidays, and the Burning Man festival. But by viewing nature as simply the opposite of culture, consumers often expedite the destruction of the experiences of nature they desire most," ...

Adolescent boys who experience violence have up to 8 times the odds of perpetrating physical and sexual intimate partner violence that same day, per South African study collecting real-time data over

Critically endangered hawksbill turtles migrate up to 1,000km from nesting to foraging grounds in the Western Caribbean, riding with and against ocean currents to congregate in popular feeding hotspot

Dengue Vaccine Initiative welcomes latest progress in vaccine development

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: